An Update on Safe Anticoagulation

Reiner K. Maier¹  Piotr Kuta¹  Thomas Renné¹,²,³

¹Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
²Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
³Center for Thrombosis and Hemostasis (CTH), Johannes Gutenberg University Medical Center, Mainz, Germany

Address for correspondence Thomas Renné, MD, PhD, Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany (e-mail: thomas@renne.net).


Abstract

Blood coagulation is essential to maintain the integrity of a closed circulatory system (hemostasis), but also contributes to thromboembolic occlusion of vessels (thrombosis). Thrombosis may cause deep vein thrombosis, pulmonary embolism, myocardial infarction, peripheral artery disease, and ischemic stroke, collectively the most common causes of death and disability in the developed world. Treatment for the prevention of thromboembolic diseases using anticoagulants such as heparin, coumarins, thrombin inhibitors, or antiplatelet drugs increase the risk of bleeding and are associated with an increase in potentially life-threatening hemorrhage, partially offsetting the benefits of reduced coagulation. Thus, drug development aiming at novel targets is needed to provide efficient and safe anticoagulation. Within the last decade, experimental and preclinical data have shown that some coagulation mechanisms principally differ in thrombosis and hemostasis. The plasma contact system protein factors XII and XI, high-molecular-weight kininogen, and plasma kallikrein specifically contribute to thrombosis, however, have minor, if any, role in hemostatic coagulation mechanisms. Inherited deficiency in contact system proteins is not associated with increased bleeding in humans and animal models. Therefore, targeting contact system proteins provides the exciting opportunity to interfere specifically with thromboembolic diseases without increasing the bleeding risk. Recent studies that investigated pharmacologic inhibition of contact system proteins have shown that this approach provides efficient and safe thrombo-protection that in contrast to classical anticoagulants is not associated with increased bleeding risk. This review summarizes therapeutic and conceptual developments for selective interference with pathological thrombus formation, while sparing physiologic hemostasis, that enables safe anticoagulation treatment.

Keywords
► coagulation
► thrombosis
► contact activation
► polyphosphate
► factor XII

Classical Anticoagulants

Thromboembolic diseases have remained the major cause of death and disability in the Western world. Thrombosis is the formation of blood clots that occlude vessels and terminate tissue perfusion leading to ischemia. Thrombosis occurs in both arterial and venous vessels resulting in myocardial infarction, ischemic stroke, and deep-vein thrombosis that eventually results in pulmonary embolism or peripheral vascular disease, respectively. Cumulatively,
thromboembolic diseases represent a major medical burden causing around one in four deaths worldwide. The incidence of thrombosis is constantly increasing due to the aging population. Therefore, novel therapeutic strategies for prophylactic and acute thrombosis treatments are needed.

Ousive clots are formed by activated platelets trapped by fibrin fibers that are produced by the blood coagulation system. Antithrombotic therapies that interfere with pathologic thrombus formation either target platelets or the blood coagulation cascade. Widely used clinical platelet inhibitors include (1) cyclooxygenase (COX), (2) purinergic receptor (P2Y) antagonists, and (3) antagonists of glycoprotein IIb/IIIa (GPIIb/IIIa). In contrast, anticoagulant drugs target single or combinations of coagulation proteins (proteases) thereby reducing thrombin and fibrin formation. The majority of anticoagulants have been known and used in patient care for decades. The polysaccharide heparin is the most commonly used classical anticoagulant drug. Following injection, heparins amplify the activity of the endogenous anticoagulant antithrombin that mainly inhibits active thrombin and factor X (FXa). The anticoagulant activity of heparin unfolds shortly after administration but depends on patients' antithrombin levels. Another class of classical anticoagulants is vitamin K antagonists (VKA; e.g., phenprocoumon and warfarin). These orally administered drugs prevent the posttranslational modification of coagulation factors II, VII, IX, and X through the blockade of vitamin K–dependent γ-glutamyl carboxylase, which catalyzes γ-carboxylation of glutamate residues within Gla-domains which is required for coagulation factor binding to cell surfaces. Defective local assembly (lateral diffusion) of the thrombin-forming enzymes largely impairs the enzymatic turnover and fibrin formation. VKAs are potent anticoagulant drugs and commonly used for prophylaxis and treatment of thrombosis; however, VKAs are indirect and unspecific inhibitors that interfere with both pathologic thrombus formation and physiologic hemostasis. Thus, VKA therapy is associated with a significant bleeding risk and regular monitoring is required to avoid hemorrhagic diathesis due to overdosing. While heparin and VKA target several coagulation factors, hirudin and recombinant/synthetic hirudin derivatives inhibit activated thrombin alone. Independent of their mode of action, classical antithrombotic agents are related with therapy-associated bleeding events. Direct oral anticoagulants (DOACs) selectively target thrombin or FXa. Due to their therapeutic range, DOACs do not require regular monitoring and are therefore predisposed for long-term anticoagulation therapy. Large studies showed that the incidence for hemorrhagic side effects is lower in antithrombotic treatments with DOACs in comparison to VKA; yet, an association with a significant bleeding risk still persists. Indeed, in the last years, specific antibodies (Idarucizumab) and recombinant modified proteins (Andexanet alfa) have been approved to block DOACs for the treatment of drug-associated hemorhages. Although antagonizing DOACs in bleeding episodes seems feasible, there is still a significant number of drug-associated bleeding diathesis that can eventually become life-threatening, such as for intracerebral hemorrhage. Taken together, currently used anticoagulants provide thrombo-protection, but confer another risk: all currently available anticoagulants increase the risk of bleeding that at least partially offsets the therapeutic benefits of reduced thrombotic risk (Table 1). Thus, the development of novel and safe anticoagulants for the prevention and treatment of thrombotic diseases is required.

The Factor XII–Driven Contact System

Factor XII (FXII) is thezymogen form of the plasma serine protease factor XIIa (FXIIa). Zymogen FXII is activated to FXIIa by limited proteolysis and proteolytic cleavage is due to enzymatic activation (“fluid phase activation”) or by its unique property to undergo autoactivation following binding (“contact”) to negatively charged artificial or biologic surfaces (“contact activation”). FXII surface-induced contact activation provides the mechanistic basis for a commonly used diagnostic coagulation assay, for example, the activated partial thromboplastin time (aPTT) that is used as a clinical parameter to measure the potential of the global plasma coagulation. FXII contact activation induced by white clay materials, celite and kaolin or the phenol antioxidant ellagic acid, is used to test the aPTT, a standard diagnostic coagulation assay that is measured more than half a billion times annually. On aged erythrocytes, FXII seems to be activated by yet to be identified protease activities. In blood vessels FXII binds to proteoglycans located on the surface of endothelial cells and this a locally produced FXIIa initiates the intrinsic pathway of coagulation via activation of its substrate factor XI (FXI). FXIIa formation also leads to the liberation of the proinflammatory mediator bradykinin (BK) by activating plasma prekallikrein to plasma kallikrein (PKa), which drives the cleavage of high-molecular-weight kininogen (HK). Serpin C1 esterase inhibitor (C1INH) is the major plasma inhibitor of FXIIa and PKa. Deficiency or a dysfunctional C1INH is associated with a BK-mediated life-threatening inherited swelling disorder, hereditary angioedema (HAE) type I or II, respectively. The proteases FXIIa, PKa, their endogenous inhibitor C1INH, FXIa, and the BK precursor HK together form the plasma contact system. Despite its importance for fibrin formation in clotting assays, FXII had been considered to have no function in vivo and research in this field was dormant for approximately 60 years. Nevertheless, studies on FXII experienced a revival following the discovery of thrombo-protection in FXII-deficient mice.

Novel Concepts in Antithrombotic Therapy

Ideally, an antithrombotic drug should have strong antithrombotic efficacy both in preventing and treating thrombosis. However, in sharp contrast to all currently used anticoagulants, its antithrombotic activity should not be associated with an increased bleeding tendency. However, in the classical textbook scheme, thrombosis (coagulation in pathologic vascular occlusions) and hemostasis (coagulation at the injury site to terminate bleeding) present the opposite
Table 1 | Overview of traditional antithrombotic therapies

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Administration</th>
<th>Mechanism</th>
<th>Indication</th>
<th>Monitoring</th>
<th>Reversal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiplatelet therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>Oral</td>
<td>Inhibition of cyclooxygenase</td>
<td>Secondary prophylaxis for myocardial infarction or ischemic stroke</td>
<td>None, but consider platelet function analysis to rule out nonresponder</td>
<td>None</td>
</tr>
<tr>
<td>Thienopyridine</td>
<td>Oral</td>
<td>P2Y receptors antagonist</td>
<td>Secondary prophylaxis for myocardial infarction or ischemic stroke</td>
<td>None, but consider platelet function analysis to rule out nonresponder</td>
<td>None</td>
</tr>
<tr>
<td>GPIIb/IIIa antagonists</td>
<td>Intravenous</td>
<td>Glycoprotein IIb/IIIa receptors</td>
<td>Prevention and treatment of venous and arterial thrombosis/thromboembolism</td>
<td>aPTT/anti-Xa assays</td>
<td>Protamine sulfate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anticoagulant therapy</th>
<th>Administration</th>
<th>Mechanism</th>
<th>Indication</th>
<th>Monitoring</th>
<th>Reversal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin/Phenprocoumon</td>
<td>Oral</td>
<td>Inhibition of vitamin K-dependent carboxylation of factor II, VII, IX, and X</td>
<td>Prevention and treatment of venous and arterial thrombosis/thromboembolism</td>
<td>INR</td>
<td>Vitamin K, prothrombin complex concentrate</td>
</tr>
<tr>
<td>Unfractionated Heparins/low-molecular-weight heparins</td>
<td>Subcutaneous/Intravenous</td>
<td>Activation of antithrombin</td>
<td>Prevention and treatment of venous and arterial thrombosis/thromboembolism</td>
<td>aPTT and anti-Xa assays</td>
<td>None</td>
</tr>
<tr>
<td>Direct oral anticoagulants (direct thrombin or factor Xa inhibitors)</td>
<td>Oral</td>
<td>Inhibition of thrombin or factor Xa</td>
<td>Prevention and treatment of venous and arterial thrombosis/thromboembolism</td>
<td>Some, but anti-Xa assays can be used to rule out substantial residual effect</td>
<td>Idarucizumab or andexanet alfa</td>
</tr>
</tbody>
</table>

Abbreviations: aPTT, activated partial thromboplastin time; INR, international normalized ratio.

Table 1

**Targeting Factor XII in Experimental Thrombosis Models**

The importance of FXII in pathologic thrombosis is not restricted to murine models. We and others have shown a critical role of the FXIIa-driven intrinsic pathway of coagulation for experimental thrombosis in large animals such as rats, rabbits, or primates, and recently in humans. To address the question which preclinical models have a more predictive value for human therapy, we had screened for antibodies against FXIIa using phage display and demonstrated that recombinant fully humanized antibody 3F7 inhibits FXIIa enzymatic activity, interferes with FXII-mediated coagulation, and blocks experimental thrombosis in mice and rabbits (Fig. 1). In an adapted extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system used for infant therapy, the clinical applicability of 3F7 was tested in rabbits. 3F7 provided thrombo-protection as efficiently as heparin; however, unlike heparin, 3F7 treatment did not impair the hemostatic capacity of animals and did not increase the bleeding risk. Our data provide the first clinically relevant antithrombotic strategy that is not complicated by excess bleeding.

In addition to 3F7, more FXII inhibitors have been developed. rHA-Infestin-4 is a recombinant inhibitor of FXIIa that is composed of the insect protein infestin-4 that has been fused to human recombinant albumin to increase its half-life and solubility. rHA-Infestin-4 therapy protected from experimental arterial and venous thrombosis and associated thromboembolic diseases such as pulmonary embolism, atherothrombosis, and ischemic strokes. Similar to 3F7 and despite its potent anticoagulant activities, physiological hemostasis remained unaffected in rHA-infestin-4-treated animals.

Inhibition of FXIIa with rHA-infestin-4 protected mice from FeCl₃-induced thrombosis in veins and arteries. In a model of silent brain ischemia in mice induced by intracerebral injection of microbeads or clot material, rHA-
infestin-4 also reduced cerebral microinfarcts but was inactive in reducing ischemia-induced inflammatory reactions.\textsuperscript{25} Consistent to the infestin-4 data, mice treated with Ir-CPI, an inhibitor of FXIIa, activated FXI and PK, were protected from lethal pulmonary embolism and stasis-induced venous thrombosis.\textsuperscript{26} Similarly, FXIIa-driven fibrin formation contributed to stasis-associated vena cava thrombosis induced by restriction of blood flow.\textsuperscript{27} H-D-Pro-Phe-Arg-chloromethyl ketone (PCK), that inhibits FXIIa and PK, interfered with lethal pulmonary embolism in murine models.\textsuperscript{28} Consistent with the genetic and pharmacologic models, antisense oligonucleotide (ASO)-mediated “knockdown” of F12 gene expression attenuated experimentally induced arterial and venous thrombosis.\textsuperscript{29} However, in contrast to “classical” anticoagulants, a significant reduction in FXII was required to achieve thrombo-protection. Thrombosis is normal in FXII heterozygous mice (F12\textsuperscript{+/-}) having 50% of normal circulating FXII and FXII needs to be reduced to less than 25% to provide safe anticoagulant activities. Supporting the key role of the FXII-driven contact system in thrombosis, mice with deficiencies in PK\textsuperscript{30,31} or HK\textsuperscript{32} are also protected from thrombosis. More comprehensive overviews about targeting FXII and contact system proteins in various experimental thrombosis models have been presented in recent reviews.\textsuperscript{33}

**Factor XI in Thrombosis**

Similar to F12\textsuperscript{-/-} mice, animals deficient in its downstream substrate of the intrinsic pathway, coagulation factor XI (FXI), were protected from FeCl\textsubscript{3}-triggered arterial thrombosis.\textsuperscript{34} However, in contrast to FXII deficiency, low FXI activity is associated with bleeding termed “hemophilia C.” Bleeding in FXI deficiency is mild; however, it is rather unpredictable, as it is not linked to circulating FXI antigen levels and biomarkers to assess vascular disease and bleeding risk in these patients are currently lacking.\textsuperscript{35} Despite the striking phenotype in FXI-deficient (F11\textsuperscript{-/-}) mice, the discovery of impaired thrombus formation in these animals did not raise much attention most probably because the underlying mechanism was misinterpreted. Originally it was believed that impaired thrombosis in F11\textsuperscript{-/-} mice resulted from defective FXI activation by thrombin that in turn was produced by tissue factor (“feedback activation loop”).\textsuperscript{36} However, later studies challenged this hypothesis. Occlusive

---

**Fig. 1** Regulation of coagulation pathways by antithrombotic agents in hemostasis and thrombosis. Vitamin K antagonists (VKA) inhibit synthesis of functional coagulation factors VII (FVII), IX (FIX), X (FX), and prothrombin, thereby limiting thrombin generation through the activated complexes tissue factor (TF):FVIIa and factor VIIIa (FVIIIa):IXa. Heparin potentiates inhibition of FXa and thrombin by binding to antithrombin (AT) III. Direct oral anticoagulants (DOACs) antagonize FXa and thrombin, while hirudin blocks specifically thrombin. Thrombin-mediated fibrinogen activation to form insoluble fibrin fibers by the extrinsic coagulation pathway (blue arrows) in hemostasis is exceeded by initiation of the intrinsic coagulation pathway (red arrows). Negatively charged surfaces activate factor XII (FXII) to FXIIa, which is enhanced by a positive feedback loop with FXIIa-mediated activation of prekallikrein (PK) to plasma kallikrein (PKa). FXIIa and PKa are inhibited by C1 esterase inhibitor (C1INH) and peptide-based inhibitor (D-Pro-Phe-Arg-chloromethyl ketone, PCK). Recombinant *Ixodes ricinus* inhibitor (Ir-CPI) blocks FXIIa and its activated substrate factor XI (FXI) in addition to PKa. Fully humanized monoclonal antibody (mAb 3F7) and infestin-4 from *Triatoma infestans* fused to recombinant human albumin (rHA-infestin-4) specifically target FXIIa and inhibit the FXIIa-mediated coagulation cascade.
thrombus formation was similarly defective in F12 \(^{-/-}\) and F11 \(^{-/-}\) mice, as well as in animals with combined deficiency in both clotting factors (F12 \(^{-/-}\)/F11 \(^{-/-}\)). Similar protection from thrombosis argues against a role of FXI “feedback activation” in thrombotic reactions in vivo but indicates that FXI is mainly activated by FXIIa in pathological platelet-mediated thrombosis. Genetic and pharmacologic targeting of FXI activity has been shown to provide thromboprotection in an array of murine and large animal models and clinical studies on FXI inhibitors in humans are well advanced. In contrast to FXII that triggers thrombo-inflammatory reactions, the role of FXI is restricted to the coagulation system. Thus, targeting FXII provides additional beneficial effects with clinical implications beyond thrombosis.

**Targeting Factor XII in Allergy and Inflammation**

In addition to its critical function for thrombosis, the FXII-driven contact system contributes to allergic disease states.\(^{37}\) Upon allergen-challenge mast cells release, the negatively charged polysaccharide heparin that acts as contact activator efficiently activates FXII. Mast cell heparin-driven contact system activation culminates in BK formation that increases vascular permeability through cytoskeleton rearrangements in endothelial cells.\(^{38,39}\) FXII contact activation by mast cell heparin has been shown to play a critical role for anaphylactic and allergic diseases both in genetically modified mouse models and patients. Thus, targeting BK generation and signaling provides a novel and alternative treatment strategy for anaphylactic attacks.

Recent findings revealed a role of FXII for SARS-CoV-2-associated lung pathology,\(^{40}\) suggesting that targeting FXII might help reduce severity and thromboembolic complications in COVID-19 patients.\(^{41}\) In contrast to FXII, HK has recently been shown to have a role in experimental liver inflammation.\(^{42}\) Together the data reveal differential roles of contact system proteins in distinct inflammatory disease states.\(^{43}\)

Notably, plasma contact system deficiencies delay the aPTT, demonstrating the dichotomous role of FXIIa for coagulation and inflammation. Patients with deficiencies in functional C1INH develop the rare life-threatening swelling disorder, HAE type I and type II (MIM #106100). C1INH deficiency aggravates activated mast cell–triggered edema with implications for swelling attacks in HAE. Besides the two classic C1INH-dependent HAE types, a third variant, HAE type III, exists in patients who have completely normal C1INH but similarly suffer from edema attacks. HAE type III (HAE with normal C1INH; FXII-HAE) is associated with missense mutations in the FXII gene resulting in a single point mutation (Thr309Lys or Thr309Arg) that leads to increased FXII enzymatic activity (“gain-of-function”). The underlying mechanism for excessive contact activation remained unknown until it was recently shown that a HAE type III–associated mutant FXII is defective in a mucin-type Thr309-linked glycosylation. Loss of glycosylation led to increased contact-mediated autoactivation ofzymogen FXII, resulting in excessive formation of BK. Intravital microscopy imaging revealed that a humanized HAE type III mouse model with inducible liver-specific expression of Thr309Lys-mutated FXII exhibited increased contact-driven microvascular leakage. The FXIIa-neutralizing antibody 3F7 and clinically used PK inhibitors blunted edema in mice and abolished BK generation in HAE type III patient plasma, suggesting that FXIIa inhibition provides a potential therapeutic strategy to interfere with excessive vascular leakage in HAE and potentially other disease states.\(^{44}\)

Moreover, application of rHA-infestin-4 was also protective in mouse models of autoimmune encephalomyelitis\(^{45}\) and anaphylactic shock,\(^{46}\) illustrating that targeting FXIIa has anti-inflammatory potential in addition to providing antithrombotic protection. Together, the data indicate that FXIIa inhibitors have broader clinical applications exceeding their use as antithrombotic drugs.

**Polyphosphate: The Natural Factor XII Contact Activator**

The in vivo activation of FXII in the initiating steps of pathologic thrombus formation has been an enigma for many years.\(^{4}\) More specific, the natural surface that induces FXII contact activation in vivo had been unknown.\(^{47}\) But for decades it has been known that activated platelets induce plasma clotting in a FXII-dependent manner,\(^{38}\) indicating that platelets expose FXII-activating agents. Following the discovery that the linear platelet-derived polymer polyphosphate (polyP) serves as the FXII-activating surface,\(^{28}\) research elucidated the role of polyP for FXIIa-mediated thrombosis and inflammation.\(^{5,49}\) (► Fig. 2). Inorganic polyP is a polyanion consisting of up to several hundred phosphates (\(P\)) linked by energy-rich phosphoanhydride bonds. The chain length of synthetic polyP determines its solubility and FXII activation capacity in plasma.\(^{50}\) While natural platelet polyP forms insoluble Ca\(^{2+}\) ion-rich nanoparticles independently of the chain length of the polyP molecule that are retained on the surfaces of procoagulant platelets.\(^{51}\) In addition to FXII activation in vivo, polyP has also been reported to modulate several other coagulation reactions in vitro; however, a potential role of these pathways remains to be shown.\(^{50}\) Similar to targeting FXIIa, interference with polyP has emerged as a novel strategy for safe inhibition of thrombosis but sparing hemostasis. To interfere with polyP activities, we developed in 2016 the first specific polyP inhibitors, based on recombinant *Escherichia coli* exopolyphosphatase (PPX) mutants.\(^{52}\) Supporting a specific function of polyP in thrombosis, targeting polyP provided thrombo-protection in vivo. Moreover, polyP was visualized as insoluble nanoparticles on the surface of procoagulant platelets in vivo.\(^{51}\) The fact that polyPs are insoluble calcium-rich particles that are deposited on activated platelet surfaces explains that procoagulant platelets trigger thrombosis in a FXIIa-dependent manner. In addition to activating FXII, polyP binding to platelet factor 4 (PF4) generates neoantigens that lead to vaccine-induced immune
thrombotic thrombocytopenia (VITT).\(^5\) Clearly, polyP is a new and exciting player in thrombosis that awaits clinical studies. Indeed, recently a fluorescence-activated cell-sorting (FACS) assay was established to measure polyP in patients using the polyP-binding domain of PPX (PPX\(_D\)) as a polyP probe.\(^5\) Furthermore, polyP levels can be quantified by chromogenic malachite green assays that measure the formation of phosphate complexes in vitro. Recently, the first regulator for polyP in mammalian systems was identified. The phosphate transporter XPR1 controls polyP in platelets in vivo, and interference with XPR1 modulates thrombosis but not hemostasis both in mouse models and human samples.\(^5\) Furthermore, the structural basis for polyP-mediated FXII activation that provides the start of polyP-triggered thrombosis and proinflammatory reactions has been elucidated.\(^5\) A specific segment of the FXII C-terminal proline-rich region (termed PR-III) of the heavy chain is required for zymogen contact activation. A FXII variant lacking this sequence can be activated by PKa; however, it is completely defective in undergoing contact activation. The identification of the FXII contact activation side opens perspectives for new coagulation assays. Antibodies directed to the PR-III region induce FXII zymogen “contact” activation fully in solution and in a stoichiometric controllable manner allowing for improved antibody-activated PTT (aaPTT) assays. In contrast to standard aPTT systems, aaPTT assays allow the very precise measurement of FXI levels in the therapeutic range of an emerging target for safe antithrombotic therapy.

**Key Points**

- Current anticoagulant drugs reduce risk of thrombosis but concomitantly increase bleeding.
- Genetic and pharmacologic inhibition of contact system factors XII, XI, PK, and HK provides potent thromboprotection without affecting physiological hemostasis.
- Neutralization of factor XII confers additional anti-inflammatory activities.

**Conflicts of Interest**
The authors declare that they have no conflict of interest.

**Acknowledgments**
This work was supported in part by grants from the German Research Society (KFO306, SFB877, and SFB841) to T.R.

**References**
2. Vara D, Mailer RK, Tarafdar A, et al. NADPH oxidases are required for full platelet activation in vitro and thrombosis in vivo but
6 Björkqvist J, Nickel KF, Stavrou E, Renné T In vivo activation and functions of the protease factor XII. Thromb Haemost 2014;112(05):868–875
8 Renné T, Schuh K, Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005;175(05):3377–3385
12 Renné T The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012;34(01):31–41
17 Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeC3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002;87(04):774–776


